Our Mission
To organise the cardiometabolic evidence base and make it universally accessible and actionable.
Our goal is to improve both the quality and the length of life for people at risk of cardiometabolic disease.
The Problem
The Evidence Exists.
The Evidence Exists.
The Care Doesn't.
Cardiometabolic disease spans cardiovascular disease, diabetes, obesity, hypertension, dyslipidaemia and metabolic renal and hepatic damage — and it is the leading cause of global mortality and morbidity.
New therapies such as GLP-1 receptor agonists, SGLT2 inhibitors and PCSK9 inhibitors exist. Yet an implementation gap means more than 75% of patients unnecessarily remain at higher risk.
The implementation gap
>75%of patients unnecessarily remain at higher risk
Still at higher riskReaching targetsPer 100 patients
Proven therapies already exist
GLP-1 receptor agonistsSGLT2 inhibitorsPCSK9 inhibitors
Closing this gap could help millions of people and save billions in healthcare spending.
Leadership & Board of Trustees
Led by clinicians and academics
Founded in 2026 by Dr. Jyothis George, the Foundation is governed by a board of trustees with academic, hospital cardiology and primary care experience.
Dr. Kavitha Sebastian Rozario
Trustee LinkedIn profileDr. Jeffrin Anthony
Trustee LinkedIn profileDr. Sinu Xavier
Trustee LinkedIn profileGlobal Scientific Advisory Board
We are assembling a global advisory board — including people living with cardiometabolic disease. If you would like to be part of it, we'd like to hear from you.
Legal formCharitable Incorporated Organisation
Registered inEngland & Wales
Charity number1216451
Founded2026